f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "", | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for publications", | | "description": "Group for publications", |
| "display_name": "Publication", | | "display_name": "Publication", |
| "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", | | "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", |
| "image_display_url": | | "image_display_url": |
| mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", | | mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", |
| "name": "publication", | | "name": "publication", |
| "title": "Publication" | | "title": "Publication" |
| } | | } |
| ], | | ], |
| "id": "f70a6ee3-5b5f-4c67-be94-a5a5d30cd5b6", | | "id": "f70a6ee3-5b5f-4c67-be94-a5a5d30cd5b6", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-09-16T08:12:00.804428", | | "metadata_created": "2021-09-16T08:12:00.804428", |
n | "metadata_modified": "2022-04-27T12:51:53.198318", | n | "metadata_modified": "2022-04-27T12:52:23.358301", |
| "name": "malawi-integrated-hiv-program-report-2015-q1", | | "name": "malawi-integrated-hiv-program-report-2015-q1", |
| "notes": "This is the 15th quarterly HIV Program report after | | "notes": "This is the 15th quarterly HIV Program report after |
| implementation of the 2011 Integrated Clinical HIV\r\nGuidelines in | | implementation of the 2011 Integrated Clinical HIV\r\nGuidelines in |
| July 2011. A summary of the key achievements between January and March | | July 2011. A summary of the key achievements between January and March |
| 2015 is provided\r\nbelow:\r\n\r\n* Scale-up of integrated HIV | | 2015 is provided\r\nbelow:\r\n\r\n* Scale-up of integrated HIV |
| services had reached the following number of sites:\r\n\r\n * | | services had reached the following number of sites:\r\n\r\n * |
| __724__ static (579 within and 145 outside of health facilities) and | | __724__ static (579 within and 145 outside of health facilities) and |
| 188 outreach HTC sites\r\n\r\n * __714__ (static) ART | | 188 outreach HTC sites\r\n\r\n * __714__ (static) ART |
| sites\r\n\r\n * __620__ PMTCT sites (Option B+, all included in | | sites\r\n\r\n * __620__ PMTCT sites (Option B+, all included in |
t | ART sites above)\r\n\r\n *__657__ Pre-ART sites\r\n\r\n * | t | ART sites above)\r\n\r\n * __657__ Pre-ART sites\r\n\r\n * |
| __641__ sites with HIV-exposed child follow-up\r\n\r\n* __500,359__ | | __641__ sites with HIV-exposed child follow-up\r\n\r\n* __500,359__ |
| persons were tested and counselled for HIV; __157,080 (31%)__ accessed | | persons were tested and counselled for HIV; __157,080 (31%)__ accessed |
| HTC for the first time;\r\n__343,279 (69%)__ were repeat testers and | | HTC for the first time;\r\n__343,279 (69%)__ were repeat testers and |
| __9,992 (3%)__ of these received confirmatory testing (after\r\nhaving | | __9,992 (3%)__ of these received confirmatory testing (after\r\nhaving |
| tested positive in the past). This is equivalent to 40% confirmatory | | tested positive in the past). This is equivalent to 40% confirmatory |
| testing coverage among\r\n__25,270__ patients initiating ART this | | testing coverage among\r\n__25,270__ patients initiating ART this |
| quarter. __31,491 (6%)__ clients received a positive result for the | | quarter. __31,491 (6%)__ clients received a positive result for the |
| first\r\ntime.\r\n\r\n* __18,765 (97%)__ of __19,436__ blood units | | first\r\ntime.\r\n\r\n* __18,765 (97%)__ of __19,436__ blood units |
| collected were screened for (at least) HIV, hepatitis B | | collected were screened for (at least) HIV, hepatitis B |
| and\r\nsyphilis.\r\n\r\n* __148,838 (91%)__ of __164,275__ women at | | and\r\nsyphilis.\r\n\r\n* __148,838 (91%)__ of __164,275__ women at |
| ANC had their HIV status ascertained; __11,727 (8%)__ of these\r\nwere | | ANC had their HIV status ascertained; __11,727 (8%)__ of these\r\nwere |
| HIV positive. __120,651 (96%)__ of __129,368__ women at maternity had | | HIV positive. __120,651 (96%)__ of __129,368__ women at maternity had |
| their HIV status ascertained\r\n__9,142 (8%)__ of these were HIV | | their HIV status ascertained\r\n__9,142 (8%)__ of these were HIV |
| positive.\r\n\r\n* __25,270__ patients started ART this | | positive.\r\n\r\n* __25,270__ patients started ART this |
| quarter.\r\n\r\n* __551,566__ patients were alive and on ART by end of | | quarter.\r\n\r\n* __551,566__ patients were alive and on ART by end of |
| March 2015. This means that 55% of the\r\nestimated 1 million HIV | | March 2015. This means that 55% of the\r\nestimated 1 million HIV |
| positive population was on ART. 1 Estimated ART coverage among people | | positive population was on ART. 1 Estimated ART coverage among people |
| in\r\nneed for treatment1 was 48% (47,962 / 101,000) for children (<15 | | in\r\nneed for treatment1 was 48% (47,962 / 101,000) for children (<15 |
| years) and 65% (503,604 /\r\n779,000) for adults.\r\n* __76%__ of | | years) and 65% (503,604 /\r\n779,000) for adults.\r\n* __76%__ of |
| adults and __77%__ of children were retained alive on ART at 12 months | | adults and __77%__ of children were retained alive on ART at 12 months |
| after initiation. Actual\r\nretention rates are thought to be about | | after initiation. Actual\r\nretention rates are thought to be about |
| 10% higher due to misclassification of \u2018silent transfers\u2019 | | 10% higher due to misclassification of \u2018silent transfers\u2019 |
| as\r\ndefaulters in clinic-based survival/retention analysis. (see | | as\r\ndefaulters in clinic-based survival/retention analysis. (see |
| section 16.4)\r\n\r\n* __481,309 (93%)__ of __517,067__ patients on | | section 16.4)\r\n\r\n* __481,309 (93%)__ of __517,067__ patients on |
| first line adult ART were on regimen 5A (TDF/3TC/EFV).\r\n\r\n* | | first line adult ART were on regimen 5A (TDF/3TC/EFV).\r\n\r\n* |
| __11,583 2 (85%)__ of an estimated __13,317__ 1 HIV infected pregnant | | __11,583 2 (85%)__ of an estimated __13,317__ 1 HIV infected pregnant |
| women in Malawi were on ART this\r\nquarter. __6,266 (59%)__ of these | | women in Malawi were on ART this\r\nquarter. __6,266 (59%)__ of these |
| were already on ART when getting pregnant and __4,317 (41%)__ | | were already on ART when getting pregnant and __4,317 (41%)__ |
| started\r\nART during pregnancy/delivery.\r\n\r\n* An additional | | started\r\nART during pregnancy/delivery.\r\n\r\n* An additional |
| __1,584__ breastfeeding women started ART due to Option B+ (in WHO | | __1,584__ breastfeeding women started ART due to Option B+ (in WHO |
| stage 1/2)\r\n\r\n* __77%__, __72%__, __69%__ and __70%__ of women | | stage 1/2)\r\n\r\n* __77%__, __72%__, __69%__ and __70%__ of women |
| started under Option B+ were retained on ART at 6, 12, 24 and 36 | | started under Option B+ were retained on ART at 6, 12, 24 and 36 |
| months after initiation, respectively.\r\n\r\n* __8,499 (7%)__ of | | months after initiation, respectively.\r\n\r\n* __8,499 (7%)__ of |
| infants discharged alive from maternity were known to be HIV exposed, | | infants discharged alive from maternity were known to be HIV exposed, |
| __7,866 (93%)__\r\nof these received ARV prophylaxis (nevirapine). | | __7,866 (93%)__\r\nof these received ARV prophylaxis (nevirapine). |
| __6,750 (65%)__ were enrolled in exposed child followup\r\nbefore age | | __6,750 (65%)__ were enrolled in exposed child followup\r\nbefore age |
| 2 months.\r\n\r\n* A total of __10,452__ HIV exposed children and | | 2 months.\r\n\r\n* A total of __10,452__ HIV exposed children and |
| __6,223__ pre-ART patients were enrolled for follow-up in\r\nHIV Care | | __6,223__ pre-ART patients were enrolled for follow-up in\r\nHIV Care |
| Clinics (HCC) during this quarter.", | | Clinics (HCC) during this quarter.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 1, | | "num_tags": 1, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:56:19.722364", | | "created": "2022-03-23T19:56:19.722364", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "c856b2a7-5354-4b41-87eb-8ca8acdb403f", | | "id": "c856b2a7-5354-4b41-87eb-8ca8acdb403f", |
| "last_modified": "2022-04-05T00:21:11.494553", | | "last_modified": "2022-04-05T00:21:11.494553", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-integrated-hiv-program-report-2015-q1", | | "dha/malawi-integrated-hiv-program-report-2015-q1", |
| "metadata_modified": "2022-04-05T00:21:11.506932", | | "metadata_modified": "2022-04-05T00:21:11.506932", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "malawi-integrated-hiv-program-report-2015-q1", | | "name": "malawi-integrated-hiv-program-report-2015-q1", |
| "package_id": "f70a6ee3-5b5f-4c67-be94-a5a5d30cd5b6", | | "package_id": "f70a6ee3-5b5f-4c67-be94-a5a5d30cd5b6", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "c1ac859651e6ae2e2be6cda5a52436240112e20789fab33c422703d516092b60", | | "c1ac859651e6ae2e2be6cda5a52436240112e20789fab33c422703d516092b60", |
| "size": 2171737, | | "size": 2171737, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| a8acdb403f/download/malawi-integrated-hiv-program-report-2015-q1.pdf", | | a8acdb403f/download/malawi-integrated-hiv-program-report-2015-q1.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi Integrated HIV Program Report 2015 Q1", | | "title": "Malawi Integrated HIV Program Report 2015 Q1", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2015" | | "year": "2015" |
| } | | } |